Charlottetown, PE – January 17, 2011 - Dr. Harold Robertson, a resident of Belfast, PEI and researcher with Neurodyn Inc. (PEI bioscience company) has recently been inducted as a Fellow of the prestigious Royal Society of Canada (RSC), the Canadian institution devoted to recognizing excellence in learning and research, as well as recognizing accomplishments in the arts, humanities and sciences.
Dr. Robertson is Professor Emeritus of Pharmacology with the Faculty of Medicine at Dalhousie University where he was Carnegie and Rockefellar Professor and Head of the Department of Pharmacology for a decade. He was the first Neuorfortis Visiting Professor at Lund University in Sweden and is co-founder of the Brain Repair Center (BRC) at Dalhousie University. Dr. Robertson holds an appointment as adjunct professor at the University of Prince Edward Island (UPEI) and is currently a member of the research team at PEI-based Neurodyn Inc.
Dr. Robertson’s scientific career has focused on research into the treatment of Parkinson’s disease and other neurological disorders. He serves on the peer review committee of the Parkinson Society of Canada and has been instrumental in the establishment of several clinical trials for treatment of Parkinson’s.
Dr. Robertson says he has a passion, not only for scientific discovery but for helping people. “In addition to discovering new facts, science has to make a difference,” said Dr. Robertson. “Hopefully, my work will make a difference for people with Parkinson’s.”
As Senior Scientific Advisor with Neurodyn, he is involved in developing treatments for neurological diseases with a special focus on Parkinson’s and Huntington’s disease.
Neurodyn is a Prince Edward Island-based biotechnology company, focused on the discovery of products for early detection and treatment of neurological diseases. From its own discovery program, the company is developing novel therapeutic, ND-602, which has demonstrated in vivo pre-clinical efficacy in Amyotrophic Lateral Sclerosis (Lou Gehrig’s disease), Parkinson’s, Alzheimer’s and Spinal Muscular Atrophy (SMA).
The company is also developing enhanced natural products for neurological diseases and offers specialty neurological Contract Research Services in ALS, Parkinson’s disease, Alzheimer’s disease, epilepsy, schizophrenia, stroke and cognitive function testing, through its wholly owned subsidiary, CNS CRO.
Ken Cawkell, CEO OF Neurodyn stated that the company is honored to have a Fellow of the Royal Society of Canada on their team. “Dr. Robertson brings a wealth of knowledge in the field of neurological disease research to Neurodyn. His contributions to our Parkinson’s disease research program have been invaluable in moving our therapeutic development program forward.”
-30-
For more information, please contact:
The Prince Edward Island BioAlliance at (902) 367-4400 or email This email address is being protected from spambots. You need JavaScript enabled to view it. or visit our website at www.peibioalliance.com.
